Study: Boston Sci's drug-eluting stent safe, despite FDA warning

Boston Scientific ($BSX) is touting a study that says its Promus stent, which administers the immunosuppressant everolimus, is safe for use, with "excellent" results over a two-year period. The drug-eluting stent was approved by the FDA last year, but the agency required Boston Sci to warn physicians that, in some cases, the stent's struts can become deformed over time, which can lead to clotting or heart attack. However, no such cases were reported in the company's study. Report